Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

Seq, a CRISPR-based method that enriches ultra-rare tumor DNA in blood by removing background wild-type DNA before sequencing ...

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after ...

A closer look at Atlas’s unconventional get-up motion shows how the robot tests balance and hardware before committing to a ...

Some younger patients with B-cell acute lymphoblastic leukemia may be able to avoid total body irradiation conditioning prior ...

Cell free RNA diagnostics market is projected to reach US$ 204.5 Mn by 2035, expanding at a CAGR of 14.5% from 2025 to 2035 ...

From enzymes and lipid nanoparticles to large-scale process design, four global innovators redefine RNA-based medicine development and delivery.

While the US transitioned to T+1 settlement for equities in 2024, can Wall Street bring further efficiency by settling in real-time using digital asset infrastructure?

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...

Lindberg had Parkinson’s disease, the neurologist said, with all the classic symptoms. PD—as the scientists she would meet ...

ServerDomes is partnering with Global Green Generation, a global engineering and construction management organization ...

Avance Biosciences has opened a 75,000-square-foot biomanufacturing facility in Northwest Houston. The facility will support ...